146 related articles for article (PubMed ID: 37403773)
1. Life-threatening Idiopathic Nonhistaminergic Acquired Angioedema With Response to Lanadelumab.
Gamboa P; Galán C; Arrien A; Segurola A; Jáuregui I
J Investig Allergol Clin Immunol; 2024 Feb; 34(1):68-70. PubMed ID: 37403773
[No Abstract] [Full Text] [Related]
2. Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency.
Suffritti C; Sartorio S; Berra S; Janu VP; Caccia S; Zanichelli A
J Allergy Clin Immunol Pract; 2023 Mar; 11(3):963-965.e1. PubMed ID: 36379410
[No Abstract] [Full Text] [Related]
3. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema.
Azofra J; Díaz C; Antépara I; Jaúregui I; Soriano A; Ferrer M
Ann Allergy Asthma Immunol; 2015 May; 114(5):418-9.e1. PubMed ID: 25747788
[No Abstract] [Full Text] [Related]
4. Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency.
Belbézier A; Boccon-Gibod I; Bouillet L
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2490-2491. PubMed ID: 33556593
[No Abstract] [Full Text] [Related]
5. [Experiencia inicial de Lanadelumab en una paciente mexicana con angioedema hereditario tipo I].
García-Rosas C; López-Tiro JJ; Contreras-Contreras A; Ruiz-Peñaloza M; Ortiz-Monteón ZE
Rev Alerg Mex; 2023 Sep; 70(4):194. PubMed ID: 37933935
[TBL] [Abstract][Full Text] [Related]
6. Lanadelumab for the prevention of attacks in hereditary angioedema.
Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
[No Abstract] [Full Text] [Related]
7. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.
Buttgereit T; Vera C; Weller K; Gutsche A; Grekowitz EM; Aykanat S; Wahn V; Krüger R; Maurer M; Magerl M
J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3744-3751. PubMed ID: 34023564
[TBL] [Abstract][Full Text] [Related]
8. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
Hwang G; Johri A; Ng S; Craig T
Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
[TBL] [Abstract][Full Text] [Related]
9. Lanadelumab to treat hereditary angioedema.
Wedi B
Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
[TBL] [Abstract][Full Text] [Related]
10. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA
BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
[TBL] [Abstract][Full Text] [Related]
11. Acquired Non-histaminergic Angioedema With C1q Autoantibody and Urticaria: A Case Report.
Kochvar AP; Cobb G; Bernabe CC; Levine T
Cureus; 2023 Aug; 15(8):e43841. PubMed ID: 37736455
[TBL] [Abstract][Full Text] [Related]
12. Angioedema without wheals: a clinical update.
Gülbahar O
Balkan Med J; 2021 Mar; 38(2):73-81. PubMed ID: 33593719
[TBL] [Abstract][Full Text] [Related]
13. Lanadelumab for the treatment of hereditary angioedema.
Wu MA
Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
[No Abstract] [Full Text] [Related]
14. Novelties in the Diagnosis and Treatment of Angioedema.
Cicardi M; Suffritti C; Perego F; Caccia S
J Investig Allergol Clin Immunol; 2016; 26(4):212-21; quiz two pages after page 221. PubMed ID: 27470642
[TBL] [Abstract][Full Text] [Related]
15. Lanadelumab: First Global Approval.
Syed YY
Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.
Bouillet L; Bocquet A; Belbezier A; Boccon-Gibod I
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):391-392. PubMed ID: 34082125
[No Abstract] [Full Text] [Related]
18. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.
Bova M; Valerieva A; Wu MA; Senter R; Perego F
Drug Des Devel Ther; 2019; 13():3635-3646. PubMed ID: 31695331
[TBL] [Abstract][Full Text] [Related]
19. Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study.
Magerl M; Schiffhorst G; Fanter L; Müller G; Hirche C; Berkemeier F; Aygören E
Allergy; 2024 Jan; 79(1):215-224. PubMed ID: 37641968
[TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate.
Riedl MA; Hinds DR; Prince PM; Alvord TM; Dosenovic S; Abdelhadi JF; Brownrigg JR; Camp CL; Machnig T; Banerji A
Allergy Asthma Proc; 2023 Jul; 44(4):275-282. PubMed ID: 37328263
[No Abstract] [Full Text] [Related]
[Next] [New Search]
